Assessments used to calculate cardiovascular disease risk in the general population may not have the same predictive power ...
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides a precision medicine portfolio update in relation ...
A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early ...
Investing.com -- Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 3.5% after the company announced positive interim data from its Phase 1/2 clinical study of MRT-2359 in combination with enzalutamide ...
A prostate-specific antigen (PSA) test is a blood test that measures a protein released in the blood by prostate cells. Both normal and cancerous prostate cells release the protein. Most of the time, ...
The FDA has approved a novel diagnostic for prostate cancer that looks to improve upon the common screener for prostate-specific antigen, known as a PSA test. The IsoPSA blood test, developed by ...
PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback